Minuteclinic Diagnostic of Massachusetts LLC
Minuteclinic Diagnostic of Massachusetts LLC was paid $12.38M by Medicaid between Jan 2018 and Dec 2024, across 85 billing codes. Its largest line is 99203, doctor's office visit, new patient (routine) — 17% of everything it billed.
MEDWAY, MA 02053
Next to other Physician Assistant providers in Massachusetts
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 36,664 | $1.31M | |
| 2019 | 34,131 | $1.21M | |
| 2020 | 47,673 | $1.04M | |
| 2021 | 195,132 | $4.26M | |
| 2022 | 115,834 | $2.29M | |
| 2023 | 78,662 | $1.34M | |
| 2024incomplete | 37,857 | $912K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 17% | 31,781 | 31,748 | $2.14M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 16% | 150,763 | 138,182 | $1.98M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 15% | 38,054 | 36,396 | $1.80M |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 14% | 60,750 | 56,829 | $1.68M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 10.0% | 22,004 | 21,185 | $1.24M |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 6.8% | 17,297 | 17,247 | $836K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 4.4% | 24,297 | 22,346 | $544K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 3.1% | 21,487 | 21,157 | $379K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2.7% | 11,487 | 10,956 | $333K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.9% | 21,080 | 20,787 | $239K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.6% | 15,527 | 8,585 | $193K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 6,778 | 6,674 | $121K |
73 more codes
| 90686 | <1% | 7,907 | $112K | |
| 90715 | <1% | 2,743 | $86K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,061 | $74K |
| 90674 | <1% | 5,524 | $68K | |
| 90746 | <1% | 1,001 | $60K | |
| 91322 | <1% | 518 | $59K | |
| 99401 | <1% | 1,942 | $48K | |
| 91320 | <1% | 480 | $47K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,101 | $46K |
| 90480 | <1% | 1,070 | $36K | |
| 86580 | <1% | 3,902 | $24K | |
| 0004A | <1% | 470 | $19K | |
| 90682 | <1% | 654 | $18K | |
| 0082A | <1% | 362 | $16K | |
| 0064A | <1% | 427 | $16K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 1,437 | $12K |
| 99201 | <1% | 436 | $12K | |
| 0134A | <1% | 320 | $12K | |
| 0124A | <1% | 271 | $11K | |
| 90750 | <1% | 227 | $10K | |
| 90707 | <1% | 296 | $10K | |
| 0081A | <1% | 190 | $8K | |
| 0001A | <1% | 173 | $8K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 252 | $7K |
| 0083A | <1% | 164 | $7K | |
| 0071A | <1% | 149 | $7K | |
| 90661 | <1% | 278 | $7K | |
| 0072A | <1% | 113 | $5K | |
| 90662 | <1% | 340 | $5K | |
| 90739 | <1% | 48 | $5K | |
| 81002 | <1% | 3,848 | $5K | |
| 0002A | <1% | 103 | $5K | |
| 90734 | <1% | 77 | $4K | |
| 90656 | <1% | 197 | $3K | |
| 0011A | <1% | 75 | $3K | |
| 99402 | <1% | 91 | $3K | |
| 90651 | <1% | 27 | $3K | |
| 0074A | <1% | 55 | $3K | |
| 90713 | <1% | 109 | $2K | |
| 0031A | <1% | 46 | $2K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 164 | $2K |
| 81025 | <1% | 428 | $2K | |
| 90673 | <1% | 25 | $1K | |
| 0154A | <1% | 30 | $1K | |
| 86308 | <1% | 230 | $1K | |
| 86328 | <1% | 29 | $912.00 | |
| 0012A | <1% | 16 | $688.17 | |
| G0008 | Administration of influenza virus vaccine | <1% | 196 | $624.84 |
| 0173A | <1% | 13 | $596.31 | |
| 90632 | <1% | 13 | $568.76 | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 12 | $540.76 |
| 90694 | <1% | 45 | $483.00 | |
| 91321 | <1% | 12 | $130.56 | |
| 1036F | <1% | 18,104 | $64.03 | |
| 91312 | <1% | 218 | $0.02 | |
| 91300 | <1% | 96 | $0.01 | |
| 3077F | 0% | 450 | $0.00 | |
| 3078F | 0% | 12,627 | $0.00 | |
| 1160F | 0% | 12,927 | $0.00 | |
| 1159F | 0% | 11,668 | $0.00 | |
| 91313 | 0% | 261 | $0.00 | |
| 91308 | 0% | 450 | $0.00 | |
| 4124F | 0% | 59 | $0.00 | |
| 4120F | 0% | 12 | $0.00 | |
| 3079F | 0% | 4,116 | $0.00 | |
| 3074F | 0% | 14,900 | $0.00 | |
| 91301 | 0% | 35 | $0.00 | |
| 3008F | 0% | 7,195 | $0.00 | |
| 3075F | 0% | 1,562 | $0.00 | |
| 91317 | 0% | 13 | $0.00 | |
| 91307 | 0% | 87 | $0.00 | |
| 91315 | 0% | 27 | $0.00 | |
| 3080F | 0% | 144 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.